BiotechTube

MN-166 (50 mg) First + Placebo First

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Opioid Abuse

Conditions

Opioid Abuse, Opioid Dependence

Trial Timeline

Nov 1, 2012 → May 1, 2017

NCT ID
NCT01740414

About MN-166 (50 mg) First + Placebo First

MN-166 (50 mg) First + Placebo First is a phase 2 stage product being developed by MediciNova for Opioid Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT01740414. Target conditions include Opioid Abuse, Opioid Dependence.

What happened to similar drugs?

8 of 20 similar drugs in Opioid Abuse were approved

Approved (8) Terminated (6) Active (7)
✅Naldemedine + PlaceboShionogiApproved
✅Polyethylene Glycol 3350 + MovantikAstraZenecaApproved
✅Naltrexone for extended-release injectable suspension + Oral naltrexoneAlkermesApproved
✅NaltrexoneAlkermesApproved
✅VIVITROL 380mgAlkermesApproved
✅methylnaltrexone + placeboBausch HealthApproved
✅Methylnaltrexone bromideBausch HealthApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01740414Phase 2Completed

Competing Products

20 competing products in Opioid Abuse

See all competitors
ProductCompanyStageHype Score
SUBLOCADEIndivior PLCPhase 3
29
SUBLOCADEIndivior PLCPhase 3
29
ASP8082 + morphine + PlaceboAstellas PharmaPhase 1
29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 1
29
ASP8062 + Placebo ASP8062 + buprenorphine/naloxoneAstellas PharmaPhase 2
27
Naldemedine + PlaceboShionogiPhase 3
40
Naldemedine + PlaceboShionogiApproved
50
NaldemedineShionogiPhase 1/2
39
Naldemedine + PlaceboShionogiPhase 3
40
Placebo + NaldemedineShionogiPhase 2
35
Naldemedine + PlaceboShionogiPhase 3
40
Naldemedine + PlaceboShionogiPhase 2
35
NaloxegolKyowa KirinPre-clinical
26
naloxegol + non-PAMORA laxativeKyowa KirinPre-clinical
18
NaloxegolKyowa KirinPre-clinical
26
NaloxegolKyowa KirinPre-clinical
26
Brenipatide + Placebo + BuprenorphineEli LillyPhase 2
42
NKTR-118 + NKTR-118 + PlaceboAstraZenecaPhase 3
32
Naloxegol + NaloxegolAstraZenecaPhase 1
29
NKTR-118 + Usual careAstraZenecaPhase 3
40